Aardvark Therapeutics Inc (AARD) Stock Price, Quote & News

Company Profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 225 7696

Website: aardvarktherapeutics.com

Address:

4370 La Jolla Village Drive, Suite 1050, San Diego, United States

focafoca99 Aug. 17 at 6:25 PM

$AARD announced a securities class-action deadline for investors on Oct 13.

0 · Reply

MoneyFairyBlessings Aug. 11 at 3:29 PM

$AARD Very bullish here. The volume is impressive considering it does not normally have any volume.

0 · Reply

55X_ROI_Q1_2026 Aug. 2 at 7:52 AM

$AARD $SLS @jfais is a pos short scumbag. $XBI said to sell SlS short +400% ago. "Through my years of working in cancer immunotherapy, I have witnessed great advances in the field, and I believe SELLAS is on the verge of such an advance. I have been impressed with the significant potential of the Company's lead product, galinpepimut-S, to successfully treat hematological and solid malignancies through a unique approach of peptide-based immunization against the WT1 oncoprotein," stated Dr. Weber. "I am excited to join the other scientists on the Company's SAB and offer the insights that I have in the area of oncoimmunology research and development.

0 · Reply

eyepeefreeley Aug. 1 at 9:49 PM

$AARD $SLS

0 · Reply

EddieH2020 Aug. 1 at 9:30 PM

$SLS Here is the link for handy reference as we go up: https://stocktwits.com/JFais/message/634612371 SLS is gonna send you and Seedy back to Peru 🤣 @OnTheBalance 😋 $XBI $SPY

1 · Reply

Yashinvest Jul. 28 at 7:09 AM

$AARD Daily chart, price doubling potential

0 · Reply

jumanah1212 Jul. 27 at 7:40 PM

$AARD head and shoulders 💸💸🚀🚀🚀🚀

0 · Reply

jumanah1212 Jul. 23 at 2:51 PM

$AARD Double Bottom pattern: Suggests a potential bullish reversal (strong support at the two bottoms) Nearby resistance: $7.90, $10.00💸💸🚀🚀

0 · Reply

StockScanners Jul. 14 at 6:01 AM

$AARD reached 7.92

0 · Reply

Reesifer Jul. 13 at 7:53 PM

$AARD added 5.95

0 · Reply

AARDVARK THERAPEUTICS, INC. (AARD) INVESTOR ALERT Investors With Large Losses in Aardvark Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

2026-08-17T11:09:12.000Z - 2 days ago

Aardvark Therapeutics reports Q2 EPS (66c), consensus (88c)

Aug 14, 2026, 12:00 PM EDT - 4 days ago

Aardvark Therapeutics Transcript: AGM 2026

Aug 11, 2026, 4:53 PM EDT - 7 days ago

Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Aug 11, 2026, 4:00 PM EDT - 7 days ago

Aardvark Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 4:00 PM EDT - 7 days ago

Aardvark Therapeutics Quarterly report: Q2 2026

Jul 10, 2026, 8:00 AM EDT - 5 weeks ago

Aardvark Therapeutics Proxy statement: Proxy filing

Jun 29, 2026, 8:00 AM EDT - 7 weeks ago

Aardvark Therapeutics Proxy statement: Proxy filing

Jun 25, 2026, 9:00 AM EDT - 7 weeks ago

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS

2026-05-15T20:00:16.000Z - 3 months ago

Aardvark Therapeutics downgraded to Underperform from Buy at BofA

NBIX RYTM

2026-05-15T15:16:12.000Z - 3 months ago

Aardvark Therapeutics price target lowered to $7 from $8 at B. Riley

2026-05-15T14:43:58.000Z - 3 months ago

Aardvark Therapeutics Inc trading halted, volatility trading pause

2026-05-15T14:36:56.000Z - 3 months ago

Aardvark Therapeutics Inc trading resumes

2026-05-15T13:30:50.000Z - 3 months ago

Aardvark Therapeutics downgraded to Neutral from Buy at BTIG

2026-05-15T08:45:48.000Z - 3 months ago

Aardvark downgraded to Underweight from Equal Weight at Morgan Stanley

2026-05-14T22:08:33.000Z - 3 months ago

Aardvark Therapeutics announces FDA clinical hold on ARD-101

May 14, 2026, 4:53 PM EDT - 3 months ago

FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome

May 14, 2026, 4:01 PM EDT - 3 months ago

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

2026-05-10T14:36:28.000Z - 3 months ago

Aardvark Therapeutics price target lowered to $18 from $20 at BofA

2026-05-07T19:19:23.000Z - 3 months ago

Aardvark Therapeutics reports Q1 EPS (99c), consensus (91c)

May 7, 2026, 8:00 AM EDT - 3 months ago

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 7, 2026, 7:00 AM EDT - 3 months ago

Aardvark Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Aardvark Therapeutics Earnings release: Q1 2026

2026-03-24T12:42:34.000Z - 5 months ago

Aardvark Therapeutics price target lowered to $8 from $32 at B. Riley

2026-03-23T21:15:11.000Z - 5 months ago

Aardvark Therapeutics files $400M mixed securities shelf

2026-03-23T20:16:52.000Z - 5 months ago

Aardvark Therapeutics reports Q4 EPS (81c), consensus (83c)

Mar 23, 2026, 4:05 PM EDT - 5 months ago

Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 23, 2026, 4:00 PM EDT - 5 months ago

Aardvark Therapeutics Annual report: Q4 2025

Mar 23, 2026, 4:00 PM EDT - 5 months ago

Aardvark Therapeutics Earnings release: Q4 2025

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Aardvark Therapeutics Registration statement: Registration filing

Mar 11, 2026, 9:00 AM EDT - 5 months ago

Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm

2026-03-02T14:01:55.000Z - 6 months ago

Aardvark Therapeutics price target lowered to $45 from $50 at Cantor Fitzgerald

2026-03-02T12:51:55.000Z - 6 months ago

Aardvark Therapeutics price target lowered to $9 from $26 at BTIG

2026-03-02T12:43:32.000Z - 6 months ago

Aardvark Therapeutics price target lowered to $21 from $35 at Oppenheimer

Feb 27, 2026, 4:05 PM EST - 6 months ago

Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome

Feb 13, 2026, 8:00 AM EST - 6 months ago

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 12, 2026, 8:00 AM EST - 6 months ago

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

Feb 12, 2026, 8:00 AM EST - 6 months ago

Aardvark Therapeutics Announces Leadership Appointments

Feb 10, 2026, 8:00 AM EST - 6 months ago

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

Dec 10, 2025, 4:05 PM EST - 8 months ago

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

Dec 4, 2025, 11:15 AM EST - 9 months ago

Aardvark Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 8:00 AM EST - 9 months ago

Aardvark Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:05 PM EST - 9 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

Nov 24, 2025, 3:00 PM EST - 9 months ago

Aardvark Therapeutics Transcript: TD Cowen Treatment Advancements in Obesity and Related Disorders Summit

Nov 13, 2025, 4:05 PM EST - 9 months ago

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Nov 13, 2025, 4:00 PM EST - 9 months ago

Aardvark Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 4:00 PM EST - 9 months ago

Aardvark Therapeutics Earnings release: Q3 2025

Nov 11, 2025, 4:40 PM EST - 10 months ago

Aardvark Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 4:05 PM EST - 10 months ago

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Nov 5, 2025, 5:00 PM EST - 10 months ago

Aardvark Therapeutics Transcript: Study Update

Nov 5, 2025, 5:00 PM EST - 10 months ago

Aardvark Therapeutics Press release: Study Update

Nov 4, 2025, 12:00 PM EST - 10 months ago

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

Nov 3, 2025, 5:55 PM EST - 10 months ago

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Nov 3, 2025, 8:00 AM EST - 10 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

Sep 30, 2025, 9:00 AM EDT - 11 months ago

Aardvark Therapeutics Transcript: Stifel Virtual Cardiometabolic Forum

Sep 23, 2025, 4:05 PM EDT - 11 months ago

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 8, 2025, 7:00 AM EDT - 1 year ago

Aardvark Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 11:30 AM EDT - 1 year ago

Aardvark Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:00 AM EDT - 1 year ago

Aardvark Therapeutics Slides: Corporate Presentation

Aug 27, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

Aug 13, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aug 12, 2025, 6:00 PM EDT - 1 year ago

Aardvark Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 6:00 PM EDT - 1 year ago

Aardvark Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

Jul 18, 2025, 8:00 AM EDT - 1 year ago

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Jun 24, 2025, 8:00 AM EDT - 1 year ago

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

May 21, 2025, 2:35 PM EDT - 1 year ago

Aardvark Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 3:30 PM EDT - 1 year ago

Aardvark Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 19, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

May 15, 2025, 12:35 PM EDT - 1 year ago

Aardvark Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 7, 2025, 4:05 PM EDT - 1 year ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

Mar 31, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Feb 12, 2025, 10:38 PM EST - 1 year ago

Aardvark Therapeutics Announces Pricing of Initial Public Offering

focafoca99 Aug. 17 at 6:25 PM

$AARD announced a securities class-action deadline for investors on Oct 13.

0 · Reply

MoneyFairyBlessings Aug. 11 at 3:29 PM

$AARD Very bullish here. The volume is impressive considering it does not normally have any volume.

0 · Reply

55X_ROI_Q1_2026 Aug. 2 at 7:52 AM

0 · Reply

eyepeefreeley Aug. 1 at 9:49 PM

$AARD $SLS

0 · Reply

EddieH2020 Aug. 1 at 9:30 PM

$SLS Here is the link for handy reference as we go up: https://stocktwits.com/JFais/message/634612371 SLS is gonna send you and Seedy back to Peru 🤣 @OnTheBalance 😋 $XBI $SPY

1 · Reply

Yashinvest Jul. 28 at 7:09 AM

$AARD Daily chart, price doubling potential

0 · Reply

jumanah1212 Jul. 27 at 7:40 PM

$AARD head and shoulders 💸💸🚀🚀🚀🚀

0 · Reply

jumanah1212 Jul. 23 at 2:51 PM

$AARD Double Bottom pattern: Suggests a potential bullish reversal (strong support at the two bottoms) Nearby resistance: $7.90, $10.00💸💸🚀🚀

0 · Reply

StockScanners Jul. 14 at 6:01 AM

$AARD reached 7.92

0 · Reply

Reesifer Jul. 13 at 7:53 PM

$AARD added 5.95

0 · Reply

Zackpedia Jul. 13 at 7:36 PM

$AARD Down to 5.95, you could’ve sold…

0 · Reply

randa1973 Jul. 13 at 4:51 PM

$AARD

0 · Reply

Zackpedia Jul. 13 at 3:03 PM

$AARD You could’ve sold when I alerted and bought back at 6.7 now if you wanted.

0 · Reply

Zipcash Jul. 13 at 2:49 PM

$AARD 6’s and $5’s bucks coming soon imo.

0 · Reply

Zackpedia Jul. 13 at 2:12 PM

$AARD Down to 7.1 now, you could’ve sold…

0 · Reply

Zipcash Jul. 13 at 1:37 PM

$AARD $6’s incoming

0 · Reply

Zipcash Jul. 13 at 11:47 AM

$AARD

0 · Reply

GSP Jul. 13 at 11:32 AM

$SUNE $AARD $SRXH $JLHL $FRTT

0 · Reply

Zipcash Jul. 13 at 1:06 AM

$AARD This pump will DUMP tomorrow!

0 · Reply

Zipcash Jul. 13 at 1:03 AM

$AARD

0 · Reply

topstockalerts Jul. 12 at 11:38 PM

Top Gainers $GMM $JZXN $NVVE $AARD $SUNE

0 · Reply

SadyK189 Jul. 12 at 11:11 PM

Top Stocks to watch next week 1 / 2: $NVVE $GMM $AARD $FTRK $WRAP NVVE: Looking good on daily chart. Key support zone at 9.60 - 10.20. Next key level to test 16.65 - 17.15. Currently at 13.50 GMM: Looking good on 4hours chart. 2.85 - 3.10 is acting as key support zone. Next key level to test 4.7 - 5. Currently at 3.88 AARD: Good close of daily candle. Key support at 6.20 - 6.55. Next key level to test 8.45 - 8.85. Currently at 7.61 FTRK: Getting up on 4hours chart. 0.49 - 0.54 is acting as key support zone. Next key level to test 0.79 - 0.83. Currently at 0.67 WRAP: Looking good on daily chart. key support zone at 1.80 - 2.05. Next key level to test 2.9 - 3.15. Currently at 2.46

0 · Reply

Market Cap	147.50M
Revenue (ttm)	0.00
Net Income (ttm)	-57.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	79,100
Avg Vol	278,872
Day's Range	N/A - N/A
Shares Out	21.88M
Stochastic %K	5%
Beta	3.80
Analysts	Sell
Price Target	$11.11